Recent studies suggest that KEAP1/NRF2 alterations in NSCLC serve as biomarkers of poor prognosis and contribute to resistance to various cancer treatments, such as chemotherapy, radiotherapy, immunotherapy, and TKI therapy (29). This evidence concerns the gene NFE2L2 and cancer.